Analysts' Actions: Con-way, Cash America, Lululemon, Stericycle

NEW YORK (TheStreet) -- RATINGS CHANGES

Alcoa (AA) was upgraded to market perform at BMO Capital. Company should see improved demand, and market sentiment for aluminum is gaining momentum, BMO Capital said. Twelve-month price target is $14.

Con-way (CNW) was upgraded at Wunderlich to buy from hold. Twelve-month price target is $57. Improving demand environment should allow the company to boost margins, Wunderlich said.

Cash America (CSH) was downgraded at FBR Capital Markets to market perform. Twelve-month price target is $46. Enova will likely weigh on near-term earnings, FBR Capital Markets said.

H&R Block (HRB) was upgraded to buy at TheStreet Ratings.

Interface (TILE) was downgraded to hold at TheStreet Ratings.

Intel (INTC) was upgraded at Morgan Stanley to equal-weight from underweight. Company is expected to have 5% revenue upside on better business demand for PCs, Morgan Stanley said. Twelve-month price target is $28.

Lululemon (LULU) was downgraded at Robert Baird to neutral from outperform. Twelve-month price target is $44. Company lacks near-term catalysts, Robert Baird said.

Lululemon was downgraded at Canaccord Genuity to hold from buy. Twelve-month price target is $42. Product fix is likely a year away, Canaccord Genuity said.

Lululemon was downgraded at Citigroup to neutral from buy. Twelve-month price target is $40. Company faces several risks to growth, Citigroup said.

Lululemon was downgraded at Wedbush to neutral from outperform. Twelve-month price target is $40. Near-term comp sales outlook is murky, Wedbush said.

Marathon Oil (MRO) was downgraded at Wells Fargo to market perform from outperform. Valuation call, Wells Fargo said. Estimates were also cut, given the sale of Norway assets, Wells Fargo said.

Pinnacle Foods (PF) was upgraded at Credit Suisse to outperform from neutral. Twelve-month price target is $36. Expect the Hillshire merger agreement to be terminated, Credit Suisse said.

Stericycle (SRCL) was upgraded at Robert Baird to outperform from neutral. Twelve-month price target is $140. Company offers growth at an attractive price, Baird said.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.

Greenberg: Valeant Claims Critics Use 'Wrong Assumptions'
4 Stocks Under $10 Making Big Moves

This article was written by a staff member of TheStreet.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says